Red Queen Therapeutics由Apple Tree Partners和哈佛医学院共同创立，以5500万美元的A轮融资和BARDA的泛流感治疗合同推出。 Red Queen Therapeutics, co-founded by Apple Tree Partners and Harvard Medical School, launched with $55M Series A funding and a BARDA contract for a pan-influenza therapeutic.

红皇后治疗技术是临床阶段生物技术,由苹果树伙伴提供55M系列A资金启动。 Red Queen Therapeutics, a clinical-stage biotech, launched with $55M Series A funding from Apple Tree Partners. 该公司侧重于为普通民众和免疫杂乱病人开发新的抗病毒治疗方法,与BARDA签订一项全流感治疗临床前期开发合同。 The company focuses on developing novel antiviral treatments for the general population and immunocompromised patients, with a contract from BARDA for preclinical development of a pan-influenza therapeutic. Red Queen的吻合脂肽平台技术由Apple Tree和哈佛医学院的Loren Walensky共同创立，可以快速设计和开发针对病毒融合抑制的新型抗病毒疗法。 Co-founded by Apple Tree and Harvard Medical School's Loren Walensky, Red Queen's stapled lipopeptide platform technology allows rapid design and development of new antiviral therapies targeting viral fusion inhibition.